Floatz logo

Docetaxel

Concurrent Chemoradiotherapy

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Concurrent Chemoradiotherapy cohort.

Asset / SponsorPhaseRating
Tislelizumab
Sun Yat-sen University
Phase 3BB
LENVATINIB
Sun Yat-sen University
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 2CCC
Surufatinib
Sun Yat-sen University
Phase 2CCC
rc48-adc
Sun Yat-sen University
Phase 2CCC
Pyrotinib
Sun Yat-sen University
Phase 2CCC

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →